Jiangxi Fushine Pharmaceutical Co Ltd, based in China, is a pharmaceutical company.
One of their notable products is SULBACTAM, with a corresponding US DMF Number 25609.
Remarkably, this DMF maintains an Active status since its submission on October 25, 2011, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 06, 2013, and payment made on December 27, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II